BridgeBio Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr Ste 250, Palo Alto, Calif...Phone Number
(650) 391-9740Website
www.bridgebio.comRevenue
$713.1 MillionStock Symbol
BBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About BridgeBio Pharma
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631.Explore more
BridgeBio Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BridgeBio Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
BridgeBio Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BridgeBio Pharma had a recent Job posting/layoffs
Product Launch: Get notified when BridgeBio Pharma launches new products
Earning: See what the market has to say on BridgeBio Pharma recently announced quarterly report
Check if BridgeBio Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once BridgeBio Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at BridgeBio Pharma
Check out if BridgeBio Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined BridgeBio Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to BridgeBio Pharma
Compare insights from companies similar to BridgeBio Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BridgeBio Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BridgeBio Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BridgeBio Pharma.
BridgeBio Pharma financials insights
Gather financial insights about BridgeBio Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series C
$135M
2019
Other Financing Round
$299.2M
2020
Debt
$475M
2021
Debt
$750M
2025
Other Financing Round
$300M
2026
Stock/Share Issuance
$1B
BridgeBio Pharma Tech Stack
A closer look at the technologies used by BridgeBio Pharma
See more technologies
Most Recent Scoops
Hiring Plans
BridgeBio Pharma has more open roles in Information Technology than it has had at any time in the past 6 months. Technologies mentioned include: ServiceNow, DocuSign, Moveworks, and SQL. Areas of expertise include: Game Ai, Reporting Tools, Integral Calculus, Data Analysis, Requirements Traceability, Process Flow Diagrams, and Software Documentation.
Hiring Plans
Open Position
Open Position
Open Position
Person-Based
Earnings, Finance
BridgeBio Pharma News & Media
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting improved clinical stability of acoramidis over tafamidisBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s rBridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 9:10 AM EDTCompany ParticipantsChinmay Shukla -...Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC
Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan. Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BridgeBio Pharma
Sign Up For FreeTo access detailed company insights
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... Read More
